2025 Annual Work Report of the Board of Directors
In 2025, the Board of Directors strictly adhered to the Company Law, Securities Law, and other relevant regulations, as well as the Articles of Association and Board Meeting Rules. With a responsible attitude towards all shareholders, the board diligently exercised its powers, effectively implemented the resolutions of the shareholders' meeting, and conducted its work with diligence, ensuring the company's sound operation and sustainable development. The following is the 2025 Annual Work Report of the Board of Directors:
1. Company Operating Performance in 2025
During the reporting period, the company achieved an operating revenue of 816.95 million yuan, a year-on-year increase of 6.96%; the net profit attributable to shareholders of the listed company was 95.72 million yuan, a year-on-year increase of 162.93%. Among the main product lines, revenue from cardiovascular system drugs was 568.81 million yuan, up 12.31% year-on-year; revenue from musculoskeletal system drugs was 182.50 million yuan, down 2.03%; and revenue from antiviral respiratory system drugs was 26.09 million yuan, up 18.46%.
In 2025, under the leadership of the Board of Directors and its Executive Committee, the company fully implemented the refined management requirements of "practical, detailed, strict, and simple," and executed the "one reduction and three increases" (reducing costs, increasing sales, increasing efficiency, and increasing cash) strategic guidelines, effectively controlling costs. The company continued to consolidate and expand its hospital market, with in-hospital sales revenue remaining the "ballast stone" of the company's performance. Leveraging existing brand and academic advantages in the hospital market, the company achieved precise extension and efficient coverage in the external market (e-commerce, OTC, channel sales, etc.), establishing a collaborative development pattern of "in-hospital + external market." During the reporting period, external market revenue was approximately 103 million yuan, accounting for 12.6% of the company's total revenue. Notably, e-commerce sales grew by 113% year-on-year. The external market sales began to take shape, laying a solid foundation for continued market development and marketing transformation.
Accompanying the pains of national medical and pharmaceutical industry reforms, the marketing reform results implemented by the company have been increasingly consolidated, and the sales team has become more professional and mature. The company has adapted to the competitive landscape following the centralized procurement of its product, WoHua® XinKeShu Pian, with a trend of price-for-volume emerging. The company insists on academic promotion, enhances product academic brand building, and continuously releases product potential. With four exclusive medical insurance pillar products as the core engine, the company drives the collaborative development of all categories, constructing a multi-field, multi-level product cluster, achieving an upgrade from "single-point breakthrough" to "multi-point support" growth model, and promoting the transformation from "four major varieties" to "variety clusters." Comprehensive factors contributed to the company's good performance during the reporting period.
2. Daily Work of the Board of Directors in 2025
(1) Operation of the Board of Directors
In 2025, the company’s Board of Directors completed its re-election and revised the Articles of Association in accordance with the amended Company Law and relevant regulatory requirements, strengthening the functions of the Audit Committee and including employee representatives in the board. A total of six board meetings were held throughout the year. The meeting details are as follows: